Torii Pharmaceutical Co., Ltd. (4551.T)

3.960,00 -15,00 (-0,38%) Börsenschluss: 03:15PM JST

Torii Pharmaceutical Co., Ltd.

Torii Nihonbashi Bldg.
4-1, Nihonbashi-Honcho 3-chome Chuo-ku
Tokyo 103-8439
Japan
81 3 3231 6811
https://www.torii.co.jp

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 583

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Goichi Matsuda	President, CEO & Representative Director	N/A	N/A	1967
Yukihiro Takashima	General Manager of Finance & Accounting Department	N/A	N/A	N/A
Mr. Masaki Sunami	Executive Officer, Head of Production Group & Production Group Leader	N/A	N/A	N/A
Mr. Atsuyuki Kakee	Managing Executive Officer, Leader of Value Creation Group & GM of Business Development Department	N/A	N/A	N/A
Mr. Katsunobu Fujiwara	Managing Executive Officer & Pharmaceutical Sales Group Leader	N/A	N/A	N/A
Mr. Nobumasa Kondo	Managing Executive Officer & Planning and Support Group Leader	N/A	N/A	1968
Noriaki Nishino	Executive Officer, Head of Pharmacovigilance & Quality Assu Grp and Quality Assurance Grp Leader	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in JPY.

Beschreibung

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.

Corporate Governance

Torii Pharmaceutical Co., Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.